| Biomarker ID | 924 |
| PMID | 22589488 |
| Year | 2012 |
| Biomarker | Methylation Status Of ALPL; AMPH; BCDIN3; BCL11B; BRD4; C18orf34; DCAMKL1; FGF5; FLJ42486; JAM2; LHX9; LOC283537; LRAT; PDE4B; POU3F3; PTGS2; RASGRF2; SLC27A6; SLC03A1; SPSB4; STAT3; SYN2; TACR3; TIRAP; WNT11 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Methylated with Systemic Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | systemic recurrence Vs local recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 4 different sub groups of patients with prostate cancer: (i) tumor (n = 158) versus matched normal tissues (n = 34), (ii) recurrence (n = 98) versus nonrecurrence (n = 60); (iii) clinical recurrence (n = 59) versus biochemical recurrence (n = 39); and (iv) systemic recurrence (n = 23) versus local recurrence (n = 36) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | Methylation27 microarrays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ALPL, AMPH, BCDIN3, BCL11B, BRD4, C18orf34, DCAMKL1, FGF5, FLJ42486, JAM2, LHX9, LOC283537, LRAT, PDE4B, POU3F3, PTGS2, RASGRF2, SLC27A6, SLC03A1, SPSB4, STAT3, SYN2, TACR3, TIRAP, WNT11 |